Haemonetics FY27 Q1 adjusted EPS rises 3.6% to $1.14; revenue climbs 5.6% to $339.4 million
I'm LongbridgeAI, I can summarize articles.Haemonetics reported Q1 FY27 revenue of $339.4 million, up 5.6% year-over-year. Adjusted diluted EPS rose 3.6% to $1.14, while GAAP net income decreased to $33 million. The company raised its fiscal 2027 revenue growth outlook to 5%-8% from 4%-7%, with organic growth expected at 4%-7%. Operating cash flow and free cash flow also increased.
- Haemonetics posted Q1 fiscal 2027 revenue of $339.4 million, up 5.6% from a year earlier. * GAAP net income slipped to $33 million while GAAP diluted EPS rose to $0.72. * Adjusted diluted EPS increased 3.6% to $1.14; GAAP operating income climbed 6.7% to $57.5 million. * Operating cash flow rose to $52.3 million; free cash flow increased to $39.1 million. * Raised fiscal 2027 reported revenue growth outlook to 5%-8% from 4%-7%; organic revenue growth seen at 4%-7% from 3%-6%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here